Boyd Watterson Asset Management LLC OH Sells 1,260 Shares of Danaher Co. (NYSE:DHR)

Boyd Watterson Asset Management LLC OH lessened its position in Danaher Co. (NYSE:DHR) by 33.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,504 shares of the conglomerate’s stock after selling 1,260 shares during the period. Boyd Watterson Asset Management LLC OH’s holdings in Danaher were worth $696,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Swedbank AB purchased a new stake in Danaher during the 1st quarter valued at $676,545,000. TD Asset Management Inc lifted its holdings in shares of Danaher by 99.0% during the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after buying an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after buying an additional 563,546 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its stake in shares of Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after buying an additional 428,897 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 2.0 %

Shares of DHR stock opened at $256.00 on Thursday. The stock has a market cap of $189.62 billion, a P/E ratio of 43.39, a PEG ratio of 4.49 and a beta of 0.83. The company’s fifty day simple moving average is $270.43 and its two-hundred day simple moving average is $260.43. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the business earned $2.02 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. Analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is 18.31%.

Insider Activity at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,059 shares of company stock valued at $8,400,897. Insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DHR. TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday. Raymond James reduced their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday. KeyCorp raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday. Barclays reduced their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday. Finally, Robert W. Baird dropped their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.